ABBOTT PARK, Illinois, USA, April 28, 2026
Abbott has announced that its next-generation Ultreon™ 3.0 AI-powered coronary imaging platform has received clearance from the U.S. Food and Drug Administration along with CE Mark approval in Europe, marking a significant dual regulatory milestone in the advancement of AI-driven coronary imaging technologies. The integrated platform combines optical coherence tomography (OCT) with artificial intelligence-enabled insights, allowing physicians to visualize coronary artery structures with high precision while receiving real-time procedural guidance. This innovation is expected to significantly enhance clinical decision-making, procedural efficiency, and patient outcomes in the treatment of coronary artery disease, positioning Ultreon 3.0 as a transformative tool in modern interventional cardiology.
Dual Regulatory Milestones Advance Global Adoption
The simultaneous FDA clearance and CE Mark certification confirm that Ultreon 3.0 meets stringent regulatory standards for safety, performance, and clinical effectiveness across both the United States and European markets. These approvals enable Abbott to expand the platform’s availability globally, reinforcing its leadership in AI-powered MedTech innovation.
The system integrates imaging and AI into a single workflow, providing physicians with a comprehensive understanding of arterial blockages, including plaque composition and vessel morphology. By delivering automated insights and actionable data in real time, the platform supports faster and more confident treatment decisions, which are critical during high-risk cardiovascular procedures.
AI Integration Enhances Precision in PCI Procedures
Advertisement
Ultreon 3.0 is specifically designed to optimize percutaneous coronary intervention (PCI) procedures, which are widely used to treat blocked coronary arteries. The platform features a one-second OCT pullback technology that captures high-resolution images using infrared light, offering superior visualization compared to conventional imaging techniques while minimizing the need for contrast agents.
This is particularly beneficial for patients with kidney disease, where reduced contrast exposure is essential. The AI-powered software analyzes plaque characteristics and vessel dimensions to guide accurate stent sizing and placement, ensuring improved blood flow and better procedural outcomes. Additionally, the system provides post-procedure assessments to confirm treatment success, enhancing overall clinical confidence and consistency.
Transforming Coronary Care Through AI and Precision Imaging
The introduction of Ultreon 3.0 represents a major step forward in the evolution of precision-guided cardiovascular care, where imaging and therapy are seamlessly integrated. By combining diagnostic clarity with therapeutic guidance, the platform enables a more personalized approach to treating complex coronary conditions. The adoption of AI in imaging workflows also contributes to standardization of care, reducing variability in outcomes and supporting better long-term patient prognosis.
From a cGxP perspective, the platform reflects adherence to rigorous quality standards, software validation, and regulatory compliance frameworks, ensuring reliability and safety in clinical use. As cardiovascular disease continues to be a leading global health burden, innovations like Ultreon 3.0 are expected to play a pivotal role in advancing minimally invasive interventions and next-generation MedTech solutions.
Source: Abbott press release
